References
[1] Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and
global spread of SARS-CoV-2. Nature 2021;600(7889):408-18.
10.1038/s41586-021-04188-6.
[2] Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. A single
dose of an adenovirus-vectored vaccine provides protection against
SARS-CoV-2 challenge. Nature communications 2020;11(1):4081.
10.1038/s41467-020-17972-1.
[3] Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety,
tolerability, and immunogenicity of a recombinant adenovirus type-5
vectored COVID-19 vaccine: a dose-escalation, open-label,
non-randomised, first-in-human trial. Lancet 2020;395(10240):1845-54.
10.1016/S0140-6736(20)31208-3.
[4] Chi X, Guo Y, Zhang G, Sun H, Zhang J, Li M, et al. Broadly
neutralizing antibodies against Omicron-included SARS-CoV-2 variants
induced by vaccination. Signal transduction and targeted therapy
2022;7(1):139. 10.1038/s41392-022-00987-z.
[5] Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored
COVID-19 vaccine in healthy adults aged 18 years or older: a randomised,
double-blind, placebo-controlled, phase 2 trial. Lancet
2020;396(10249):479-88. 10.1016/S0140-6736(20)31605-6.
[6] Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous
AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a
randomized phase 4 trial. Nature medicine 2022;28(2):401-9.
10.1038/s41591-021-01677-z.
[7] Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, et al. Safety,
tolerability, and immunogenicity of an aerosolised adenovirus type-5
vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report
of an open-label and randomised phase 1 clinical trial. The Lancet
Infectious diseases 2021;21(12):1654-64. 10.1016/S1473-3099(21)00396-0.
[8] Terreri S, Piano Mortari E, Vinci MR, Russo C, Alteri C, Albano
C, et al. Persistent B cell memory after SARS-CoV-2 vaccination is
functional during breakthrough infections. Cell Host Microbe
2022;30(3):400-8 e4. 10.1016/j.chom.2022.01.003.
[9] Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens
K, et al. Seasonal coronavirus protective immunity is short-lasting.
Nature medicine 2020;26(11):1691-3. 10.1038/s41591-020-1083-1.
[10] Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et
al. SARS-CoV-2-reactive T cells in healthy donors and patients with
COVID-19. Nature 2020;587(7833):270-4. 10.1038/s41586-020-2598-9.
[11] Schulien I, Kemming J, Oberhardt V, Wild K, Seidel LM, Killmer
S, et al. Characterization of pre-existing and induced
SARS-CoV-2-specific CD8(+) T cells. Nature medicine 2021;27(1):78-85.
10.1038/s41591-020-01143-2.
[12] Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de
Sandt CE, et al. Breadth of concomitant immune responses prior to
patient recovery: a case report of non-severe COVID-19. Nature medicine
2020;26(4):453-5. 10.1038/s41591-020-0819-2.
[13] McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH,
Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in
rhesus macaques. Nature 2021;590(7847):630-4.
10.1038/s41586-020-03041-6.
[14] Habel JR, Nguyen THO, van de Sandt CE, Juno JA, Chaurasia P,
Wragg K, et al. Suboptimal SARS-CoV-2-specific CD8(+) T cell response
associated with the prominent HLA-A*02:01 phenotype. Proceedings of the
National Academy of Sciences of the United States of America
2020;117(39):24384-91. 10.1073/pnas.2015486117.
[15] Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin
JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals
with Asymptomatic or Mild COVID-19. Cell 2020;183(1):158-68 e14.
10.1016/j.cell.2020.08.017.
[16] Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, et al.
An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls
viral replication and is associated with less severe COVID-19 disease.
Nature immunology 2022;23(1):50-61. 10.1038/s41590-021-01084-z.
[17] Joosten SA, Sullivan LC, Ottenhoff TH. Characteristics of HLA-E
Restricted T-Cell Responses and Their Role in Infectious Diseases. J
Immunol Res 2016;2016:2695396. 10.1155/2016/2695396.
[18] Bansal A, Gehre MN, Qin K, Sterrett S, Ali A, Dang Y, et al.
HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural
infection. J Clin Invest 2021;131(16). 10.1172/JCI148979.
[19] Sharpe HR, Bowyer G, Brackenridge S, Lambe T. HLA-E: exploiting
pathogen-host interactions for vaccine development. Clin Exp Immunol
2019;196(2):167-77. 10.1111/cei.13292.
[20] Kraemer T, Blasczyk R, Bade-Doeding C. HLA-E: a novel player
for histocompatibility. J Immunol Res 2014;2014:352160.
10.1155/2014/352160.
[21] Caccamo N, Sullivan LC, Brooks AG, Dieli F. Harnessing
HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients
with severe COVID-19. Br J Haematol 2020;190(4):e185-e7.
10.1111/bjh.16895.
[22] Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr
M, et al. BNT162b2 vaccine induces neutralizing antibodies and
poly-specific T cells in humans. Nature 2021;595(7868):572-7.
10.1038/s41586-021-03653-6.
[23] Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Munoz
Sandoval D, et al. Immune boosting by B.1.1.529 (Omicron) depends on
previous SARS-CoV-2 exposure. Science 2022;377(6603):eabq1841.
10.1126/science.abq1841.
[24] Rodda LB, Morawski PA, Pruner KB, Fahning ML, Howard CA, Franko
N, et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid
immunity. Cell 2022;185(9):1588-601 e14. 10.1016/j.cell.2022.03.018.
[25] Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. SARS-CoV-2
Spike 1 Protein Controls Natural Killer Cell Activation via the
HLA-E/NKG2A Pathway. Cells 2020;9(9). 10.3390/cells9091975.
[26] Hammer Q, Dunst J, Christ W, Picarazzi F, Wendorff M, Momayyezi
P, et al. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that
abrogates inhibition of NKG2A-expressing NK cells. Cell Rep
2022;38(10):110503. 10.1016/j.celrep.2022.110503.
[27] Grant EJ, Nguyen AT, Lobos CA, Szeto C, Chatzileontiadou DSM,
Gras S. The unconventional role of HLA-E: The road less traveled.
Molecular immunology 2020;120:101-12. 10.1016/j.molimm.2020.02.011.
[28] Tennoe S, Gheorghe M, Stratford R, Clancy T. The T Cell Epitope
Landscape of SARS-CoV-2 Variants of Concern. Vaccines (Basel)
2022;10(7). 10.3390/vaccines10071123.
[29] Weingarten-Gabbay S, Klaeger S, Sarkizova S, Pearlman LR, Chen
DY, Gallagher KME, et al. Profiling SARS-CoV-2 HLA-I peptidome reveals T
cell epitopes from out-of-frame ORFs. Cell 2021;184(15):3962-80 e17.
10.1016/j.cell.2021.05.046.